EMERYVILLE -
The new workflow and reagents, to be commercially available by the end of the year, enable rapid, automated generation of antigen-specific, functional monoclonal antibodies from human memory B cells, building on prior workflows and reagents that used rabbit memory B cells and mouse plasma cells. Directly accessing the human repertoire with new workflow and reagents allows researchers to find more physiologically relevant and efficacious antibodies faster in a rapidly evolving biomedical field aimed at addressing infectious, autoimmune, and oncologic diseases.
Using the Opto Memory B Discovery Human workflow, PhenomeX estimates customers can: Prepare memory B cells from a wide variety of traditional enrichment strategies for screening in
(C) 2023 Electronic News Publishing, source